It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. "Neupro® Patch", a Dopaminergic, Anti-Parkinsonian Drug,Will Become Available in Japan in an Additional New Dosage, "Neupro Patch 18 mg"

May 25, 2016

Otsuka Pharmaceutical Co., Ltd.


"Neupro® Patch", a Dopaminergic, Anti-Parkinsonian Drug,
Will Become Available in Japan in an Additional New Dosage, "Neupro Patch 18 mg"

Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Tatsuo Higuchi) announces that "Neupro Patch" (generic name: rotigotine), a treatment for Parkinson's disease, will become available in Japan from June 1 with an additional new dosage amount, "Neupro Patch 18 mg".

"Neupro Patch", a therapeutic agent for Parkinson's disease and Restless Legs Syndrome*1, was launched in Japan in February 2013 and is the only transdermal dopamine agonist*2 formulation available in the world. "Neupro Patch" is applied to the skin simply and easily, just once daily, because it is a sustained release formulation that maintains blood drug concentrations and stable efficacy over a 24-hour period.

  1. 1Dopamine agonists work by binding to and stimulating dopamine receptors
  2. 2Symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults

Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases